Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
In a new post tied to DMA-related decisions, Google’s top European executive argues that rules affecting Android permissions and data access could expose private searches and device capabilities to unfamiliar third parties, while the company also points to a separate $5 million push to scale an AI jobs platform in Ukraine.
THE APEX TIMES
THE APEX TIMES
Intel shares slid nearly 8% in a fast move after television host Jim Cramer highlighted the chipmaker as a favorite, with the decline coming even as markets pointed to an ASML milestone.
THE APEX TIMES
The data-center developer Soluna said it has appointed Ryan Carver, described as a Microsoft hyperscale executive, to lead the company’s artificial intelligence efforts.
THE APEX TIMES
The engine maker said its second-quarter results exceeded analyst estimates and it lifted guidance for the full year, citing stronger growth in commercial services.
THE APEX TIMES
A new round of analyst updates is nudging UnitedHealth Group’s perceived fair value higher, with estimates rising to about $424 from roughly $411 previously, according to a market update published on July 16, 2026.
THE APEX TIMES
Healthcare insurer UnitedHealth rallied sharply after reporting results that beat expectations, even as semiconductor-linked weakness weighed on Nasdaq-related sentiment before the market open.
THE APEX TIMES
UnitedHealth reported better-than-expected Q2 CY2026 revenue, even as sales were flat year over year at $112 billion. The company also posted non-GAAP earnings of $6.38 per share.
THE APEX TIMES
The ride-hailing company is moving deeper into restaurant delivery through an acquisition of Germany-based Delivery Hero, a deal valued at €12.7 billion (about $14.6 billion), according to a report. Companies did not outline detailed terms in the cited post.
THE APEX TIMES
AtaiBeckley surged about 50% ahead of the open after a market report said Eli Lilly is in talks to buy the psychedelic-focused company at a premium. Neither company confirmed the negotiations in the posting that circulated to markets.
